Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices

Explore recent data surrounding contemporary HCC treatment with this program featuring expert commentaries, an on-demand Webcast, and downloadable slides.
Richard Finn, MD

ClinicalThought

Atezolizumab plus bevacizumab was recently approved as first-line systemic therapy for patients with advanced HCC. Read an expert’s thoughts how this new approach will fit into contemporary treatment paradigms.

Richard Finn, MD Released: September 15, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Eisai
Exelixis, Inc.
Genentech, a member of the Roche Group
Lilly
Merck Sharp & Dohme Corp

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue